样式: 排序: IF: - GO 导出 标记为已读
-
Cancer anorexia‐cachexia syndrome is characterized by more than one inflammatory pathway J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-14 Bruno Gagnon, Jessica Murphy, David Simonyan, Claudia A. Penafuerte, Jacinthe Sirois, Martin Chasen, Michel L. Tremblay
BackgroundThe interdependence of cytokines and appetite‐modifying hormones implicated in cancer anorexia‐cachexia syndrome (CACS) remains unclear. This study aimed to regroup these cytokines and hormones into distinct inflammatory (or non‐inflammatory) pathways and determine whether these pathways can classify patients with CACS phenotypes.MethodsClinical characteristics of 133 patients [61.7% male;
-
The relationship between weight gain during chemotherapy and outcomes in patients with advanced non‐small cell lung cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-12 Eric J. Roeland, Florian J. Fintelmann, Fiona Hilton, Ruoyong Yang, Ed Whalen, Lisa Tarasenko, Roberto A. Calle, Philip D. Bonomi
BackgroundThis post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non‐small cell lung cancer (NSCLC) receiving first‐line platinum‐based chemotherapy.MethodsData were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first
-
Frailty phenotype as mediator between systemic inflammation and osteoporosis and fracture risks: A prospective study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-12 Dongsheng Di, Haolong Zhou, Zhangbo Cui, Jianli Zhang, Qian Liu, Tingting Yuan, Tingting Zhou, Xiao Luo, Danyang Ling, Qi Wang
BackgroundSystemic inflammation and frailty have been implicated in osteoporosis (OP) and fracture risks; however, existing evidence remains limited and inconclusive. This study aimed to assess the associations of systemic inflammation and frailty phenotype with incident OP and fracture and to evaluate the mediating role of frailty phenotype.MethodsThe present study analysed data from the UK Biobank
-
Comment on “A promising prognostic grading system incorporating weight loss and inflammation in patients with advanced cancer” by Zhang et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-03-12 Josh McGovern, Donald C. McMillan
Dear Editor, We read the manuscript ‘A promising prognostic grading system incorporating weight loss and inflammation in patients with advanced cancer’ by Zhang and co-workers with considerable interest. The authors are to be congratulated for carrying out a large multicentre prospective cohort study of 11 423 patients with advanced cancer that examined the prognostic value of the combination of weight
-
Control of muscle satellite cell function by specific exercise‐induced cytokines and their applications in muscle maintenance J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-20 Qian Guo, Qing Luo, Guanbin Song
Exercise is recognized to play an observable role in improving human health, especially in promoting muscle hypertrophy and intervening in muscle mass loss‐related diseases, including sarcopenia. Recent rapid advances have demonstrated that exercise induces the release of abundant cytokines from several tissues (e.g., liver, muscle, and adipose tissue), and multiple cytokines improve the functions
-
The optimal cut-off value of five-time chair stand test for assessing sarcopenia among Chinese community-dwelling older adults J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-11 Yu-Hua Li, Xiu-Hua Wang, Shi Ya, Huang Jiaoling, Nan Hua
The five-time chair stand test (5CST) as an indicator of muscle strength and physical function is the first step in assessing sarcopenia. We aimed to determine the optimal cut-off value of the 5CST for assessing older adults with sarcopenia in the Chinese community.
-
Bed-rest and exercise remobilization: Concurrent adaptations in muscle glucose and protein metabolism J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-12 Natalie F. Shur, Elizabeth J. Simpson, Hannah Crossland, Despina Constantin, Sally M. Cordon, Dumitru Constantin-Teodosiu, Francis B. Stephens, Matthew S. Brook, Philip J. Atherton, Kenneth Smith, Daniel J. Wilkinson, Olivier E. Mougin, Christopher Bradley, Ian A. Macdonald, Paul L. Greenhaff
Bed-rest (BR) of only a few days duration reduces muscle protein synthesis and induces skeletal muscle atrophy and insulin resistance, but the scale and juxtaposition of these events have not been investigated concurrently in the same individuals. Moreover, the impact of short-term exercise-supplemented remobilization (ESR) on muscle volume, protein turnover and leg glucose uptake (LGU) in humans is
-
Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-11 Ola Magne Vagnildhaug, Trude R. Balstad, Inger Ottestad, Asta Bye, Christine Greil, Jann Arends, Vickie Baracos, Leo R. Brown, Olav F. Dajani, Ross D. Dolan, Marie Fallon, Eilidh Fraser, Aleksandra Grzyb, Marianne J. Hjermstad, Gunnhild Jakobsen, Stein Kaasa, James McDonald, Iain Philips, Judith Sayers, Melanie R. Simpson, Mariana S. Sousa, Richard J.E. Skipworth, Barry J.A. Laird, Tora S. Solheim
There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and evaluate endpoints used to assess appetite and dietary intake in cancer cachexia clinical trials. A search for studies published from 1 January 1990 until 2 June 2021 was conducted
-
Chronic aryl hydrocarbon receptor activity impairs muscle mitochondrial function with tobacco smoking J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-09 Liam F. Fitzgerald, Jacob Lackey, Ahmad Moussa, Sohan V. Shah, Ana Maria Castellanos, Shawn Khan, Martin Schonk, Trace Thome, Zachary R. Salyers, Nishka Jakkidi, Kyoungrae Kim, Qingping Yang, Russell T. Hepple, Terence E. Ryan
Accumulating evidence has demonstrated that chronic tobacco smoking directly contributes to skeletal muscle dysfunction independent of its pathological impact to the cardiorespiratory systems. The mechanisms underlying tobacco smoke toxicity in skeletal muscle are not fully resolved. In this study, the role of the aryl hydrocarbon receptor (AHR), a transcription factor known to be activated with tobacco
-
Chronic hypoxia impairs skeletal muscle repair via HIF-2α stabilization J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-09 Amelia Yin, Wenyan Fu, Anthony Elengickal, Joonhee Kim, Yang Liu, Anne Bigot, Kamal Mamchaoui, Jarrod A. Call, Hang Yin
Chronic hypoxia and skeletal muscle atrophy commonly coexist in patients with COPD and CHF, yet the underlying physio-pathological mechanisms remain elusive. Muscle regeneration, driven by muscle stem cells (MuSCs), holds therapeutic potential for mitigating muscle atrophy. This study endeavours to investigate the influence of chronic hypoxia on muscle regeneration, unravel key molecular mechanisms
-
Prognostic value of initial and longitudinal changes in body composition in metastatic pancreatic cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-08 Min Woo Lee, Sun Kyung Jeon, Woo Hyun Paik, Jeong Hee Yoon, Ijin Joo, Jeong Min Lee, Sang Hyub Lee
Sarcopenia or visceral adipose tissue has been reported to be related to pancreatic cancer prognosis. However, clinical relevance of the comprehensive analysis of body compositions and their longitudinal changes is lacking. This study analysed the association between body composition changes after chemotherapy and survival in patients with metastatic pancreatic cancer.
-
Longitudinal association between muscle and bone loss: Results of US and Japanese cohort studies J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-08 Yusuke Osawa, Yang An, Yukiko Nishita, Yasumoto Matsui, Marie Takemura, Eleanor M. Simonsick, Hiroshi Shimokata, Rei Otsuka, Hidenori Arai, Luigi Ferrucci
Muscle and bone are physiologically interconnected, but joint changes of muscle and bone with aging, and whether the muscle-bone changes are different by sex and by country has been little studied. We examined longitudinal associations of bone mineral density (BMD) and muscle mass or muscle strength in community-dwelling 65 years or older in the United States and Japan.
-
Correction to ‘Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease’ by Lakshman Kumar et al. J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-07
In Preeti Lakshman Kumar, Ava C. Wilson, Alison Rocco, Michael H. Cho, Emily Wan, Brian D. Hobbs, George R. Washko, Victor E. Ortega, Stephanie A. Christenson, Xingnan Li, J. Michael Wells, Surya P. Bhatt, Dawn L. DeMeo, Sharon M. Lutz, Harry Rossiter, Richard Casaburi, Stephen I. Rennard, David A. Lomas, Wassim W. Labaki, Ruth Tal-Singer, Russel P. Bowler, Craig P. Hersh, Hemant K. Tiwari, Mark Dransfield
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-02-01
No abstract is available for this article.
-
Influence of skeletal muscle and intermuscular fat on postoperative complications and long-term survival in rectal cancer patients J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-31 Tong Nie, Feihong Wu, Yixin Heng, Wentai Cai, Zhihao Liu, Le Qin, Yinghao Cao, Chuansheng Zheng
The body composition of patients with rectal cancer potentially affects postoperative outcomes. This study explored the correlations between skeletal muscle and adipose tissue quantified by computed tomography (CT) with postoperative complications and long-term prognosis in patients with rectal cancer after surgical resection.
-
The burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-30 Hsi-Yu Lai, Shih-Tsung Huang, Stefan D. Anker, Stephan von Haehling, Masahiro Akishita, Hidenori Arai, Liang-Kung Chen, Fei-Yuan Hsiao
Frailty often coexists with heart failure (HF), which significantly aggravates the clinical outcomes of older adults. However, studies investigating the interplay between frailty and HF in older adults are scarce. We aimed to assess the prevalence of frailty using the cumulative deficit approach and evaluate the impacts of frailty on health utilization, use of HF-related medications and adverse clinical
-
Muscle parameters in fragility fracture risk prediction in older adults: A scoping review J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-29 Colin Vendrami, Enisa Shevroja, Elena Gonzalez Rodriguez, Guillaume Gatineau, Jolanda Elmers, Jean-Yves Reginster, Nicholas C. Harvey, Olivier Lamy, Didier Hans
Half of osteoporotic fractures occur in patients with normal/osteopenic bone density or at intermediate or low estimated risk. Muscle measures have been shown to contribute to fracture risk independently of bone mineral density. The objectives were to review the measurements of muscle health (muscle mass/quantity/quality, strength and function) and their association with incident fragility fractures
-
RORα–GABP–TFAM axis alleviates myosteatosis with fatty atrophy through reinforcement of mitochondrial capacity J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-25 Hyeon-Ji Kim, Sang-Heon Lee, Cheolhee Jeong, Yong-Hyun Han, Mi-Ock Lee
Fat infiltration in muscle, called ‘myosteatosis’, precedes muscle atrophy, which subsequently results in sarcopenia. Myosteatosis is frequently observed in patients with nonalcoholic fatty liver disease (NAFLD). We have previously reported that retinoic acid receptor-related orphan receptor-α (RORα) regulates mitochondrial dynamics and mitophagy in hepatocytes, resulting in an alleviation of NAFLD
-
Sizing and mending of appendicular muscle mass for hydration during the 12-lead electrocardiogram: True incidence of sarcopenia in heart failure J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-26 Falko Skrabal, Steven B. Heymsfield, Katharina Skrabal, Thomas Weber, Friedrich Fruhwald, Jana Windhaber, Samy Mady
Our aim was to develop and evaluate a method for the measurement of muscle mass during the 12-channel electrocardiogram (ECG), to determine the incidence of sarcopenia in patients with overhydration and to correct it for congestion.
-
Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-24 Marvery P. Duarte, Lucas S. Almeida, Silvia G.R. Neri, Juliana S. Oliveira, Thomas J. Wilkinson, Heitor S. Ribeiro, Ricardo M. Lima
Sarcopenia is a risk factor for adverse clinical outcomes in chronic kidney disease (CKD) patients, including mortality. Diagnosis depends on adopted consensus definition and cutoff values; thus, prevalence rates are generally heterogeneous. We conducted a systematic review and meta-analysis to investigate the global prevalence of sarcopenia and its traits across the wide spectrum of CKD. A systematic
-
Skeletal muscle and visceral adipose radiodensities are pre-surgical, non-invasive markers of aggressive kidney cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-24 Helena Furberg, Patrick T. Bradshaw, Andrea Knezevic, Linnea Olsson, Stacey Petruzella, Emily Stein, Mike Paris, Jessica Scott, Oguz Akin, A. Ari Hakimi, Paul Russo, Alejandro Sanchez, Bette Caan, Marina Mourtzakis
Most studies on body composition in kidney cancer have been conducted among patients with metastatic disease. Given that aggressive tumours can adversely impact body composition and even non-metastatic tumours can be aggressive, we evaluated associations between pre-surgical body composition features and tumour pathological features in patients with non-metastatic clear cell renal cell cancer (ccRCC)
-
A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-06 Joris Mallard, Elyse Hucteau, Laura Bender, Fabien Moinard-Butot, Emma Rochelle, Lauréline Boutonnet, Antoine Grandperrin, Roland Schott, Carole Pflumio, Philippe Trensz, Michal Kalish-Weindling, Anne-Laure Charles, Bernard Gény, Fabrice Favret, Xavier Pivot, Thomas J. Hureau, Allan F. Pagano
Breast cancer patients are commonly treated with sequential administrations of epirubicin–cyclophosphamide (EC) and paclitaxel (TAX). The chronic effect of this treatment induces skeletal muscle alterations, but the specific effect of each chemotherapy agent is unknown. This study aimed to investigate the effect of EC or TAX administration on skeletal muscle homeostasis in breast cancer patients.
-
A randomized controlled pilot trial of anakinra and pioglitazone for protein metabolism in patients on maintenance haemodialysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2024-01-04 Lale A. Ertuglu, Serpil Muge Deger, Aseel Alsouqi, Adriana Hung, Jorge Gamboa, Cindy Mambungu, Feng Sha, Edward Siew, Naji N. Abumrad, T. Alp Ikizler
Chronic inflammation and insulin resistance are highly prevalent in patients on maintenance haemodialysis (MHD) and are strongly associated with protein energy wasting. We conducted a pilot, randomized, placebo-controlled trial of recombinant human interleukin-1 receptor antagonist (IL-1ra) and pioglitazone to explore the safety, feasibility and efficacy for insulin-mediated protein metabolism in patients
-
Issue Information J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-26
No abstract is available for this article.
-
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: Update 2023 J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-26 Stephan von Haehling, Andrew J.S. Coats, Stefan D. Anker
The Journal of Cachexia, Sarcopenia and Muscle (JCSM) aims to publish articles with relevance to wasting disorders and illnesses of the muscle in the broadest sense. In order to avoid publication of inappropriate articles and to avoid protracted disputes, the Editors have established ethical guidelines that detail a number of regulations to be fulfilled prior to submission to the journal. This article
-
With Appreciation J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-26
We thank the following individuals who served as manuscript reviewers for The Journal of Cachexia, Sarcopenia and Muscle (JCSM) in 2023. We highly appreciate their efforts. Fair, conscientious and timely peer reviews contribute to the success of JCSM. The Editors.
-
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-29 Andrew J.S. Coats, Javed Butler, Hiroyuki Tsutsui, Wolfram Doehner, Gerasimos Filippatos, João Pedro Ferreira, Michael Böhm, Vijay K. Chopra, Subodh Verma, Matias Nordaby, Tomoko Iwata, Daisuke Nitta, Piotr Ponikowski, Faiez Zannad, Milton Packer, Stefan D. Anker
Frailty is a severe, common co-morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on the clinical benefits of sodium glucose co-transporter 2 (SGLT2) inhibition in HFpEF have been described in only a limited number of trials. Whether
-
A novel biomarker of fibrofatty replacement in dystrophinopathies identified by integrating transcriptome, magnetic resonance imaging, and pathology data J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-26 Zhihao Xie, Chang Liu, Chengyue Sun, Yanyu Lu, Shiyi Wu, Yilin Liu, Qi Wang, Yalan Wan, Yikang Wang, Meng Yu, Lingchao Meng, Jianwen Deng, Wei Zhang, Zhaoxia Wang, Chunxia Yang, Yun Yuan, Zhiying Xie
We aimed to analyse genome-wide transcriptome differences between Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) patients and identify biomarkers that correlate well with muscle magnetic resonance imaging (MRI) and histological fibrofatty replacement in both patients, which have not been reported.
-
Artificial intelligence-based analysis of body composition predicts outcome in patients receiving long-term mechanical circulatory support J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-26 Isabell Anna Just, Felix Schoenrath, Luise Roehrich, Emanuel Heil, Julia Stein, Timo Alexander Auer, Uli Fehrenbach, Evgenij Potapov, Natalia Solowjowa, Felix Balzer, Dominik Geisel, Juergen Braun, Georg Boening
Obesity is a known cardiovascular risk factor and associated with higher postoperative complication rates in patients undergoing cardiac surgery. In heart failure (HF), conflicting evidence in terms of survival has been reported, whereas sarcopenia is associated with poor prognosis. An increasing number of HF patients require left ventricular assist device (LVAD) implantations. The postoperative mortality
-
The age-related obesity paradigm: results from two large prospective cohort studies J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-25 Yi-Zhong Ge, Tong Liu, Li Deng, Qi Zhang, Chen-An Liu, Guo-Tian Ruan, Hai-Lun Xie, Meng-Meng Song, Shi-Qi Lin, Qin-Hua Yao, Xian Shen, Han-Ping Shi
The obesity paradigm has been a health concern globally for many years, its meaning is controversial. In this study, we assess the characteristics and causes of obesity paradigm and detail the mediation of obesity and inflammation on survival.
-
Prevalence of and risk factors for sarcopenia in community-dwelling people: The Vietnam Osteoporosis Study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-25 Duy K. Hoang, Minh C. Doan, Nhan M. Le, Huy G. Nguyen, Lan T. Ho-Pham, Tuan V. Nguyen
Sarcopenia is a geriatric disease characterized by the progressive and generalized loss of skeletal lean mass and strength with age. The prevalence of sarcopenia in the Vietnamese population is unknown. This study sought to estimate the prevalence of and risk factors for sarcopenia among community-dwelling individuals in Vietnam.
-
Shape phenotype of thigh fat and muscle and risk of major adverse cardiovascular events after fragility hip fracture J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-21 Sheen-Woo Lee, Seung-Chan Kim, Jeong-Eun Yi
Although sarcopenia has been recognized as a predictor of mortality in elderly patients with hip fracture, the association of thigh fat and muscle with cardiovascular (CV) outcome remains unclear. We examined the impact of computed tomography (CT)-derived shape features of thigh fat and muscle on major adverse CV events (MACE) in elderly patients with hip fracture.
-
Marked irregular myofiber shape is a hallmark of human skeletal muscle ageing and is reversed by heavy resistance training J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-20 Casper Soendenbroe, Anders Karlsen, Rene B. Svensson, Michael Kjaer, Jesper L. Andersen, Abigail L. Mackey
Age-related loss of strength is disproportionally greater than the loss of mass, suggesting maladaptations in the neuro-myo-tendinous system. Myofibers are often misshaped in aged and diseased muscle, but systematic analyses of large sample sets are lacking. Our aim was to investigate myofiber shape in relation to age, exercise, myofiber type, species and sex.
-
Three-dimensional body composition parameters using automatic volumetric segmentation allow accurate prediction of colorectal cancer outcomes J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-20 Aiya Bimurzayeva, Min Jung Kim, Jong-Sung Ahn, Ga Yoon Ku, Dokyoon Moon, Jinsun Choi, Hyo Jun Kim, Han-Ki Lim, Rumi Shin, Ji Won Park, Seung-Bum Ryoo, Kyu Joo Park, Han-Jae Chung, Jong-Min Kim, Sang Joon Park, Seung-Yong Jeong
Parameters obtained from two-dimensional (2D) cross-sectional images have been used to determine body composition. However, data from three-dimensional (3D) volumetric body images reflect real body composition more accurately and may be better predictors of patient outcomes in cancer. This study aimed to assess the 3D parameters and determine the best predictive factors for patient prognosis.
-
Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-20 Andrea N. Riner, Kelly M. Herremans, Vignesh Vudatha, Song Han, Xufeng Qu, Jinze Liu, Nitai Mukhopadhyay, Devon C. Freudenberger, Thomas J. George, Sarah M. Judge, Andrew R. Judge, Steven J. Hughes, Jose G. Trevino
Pancreatic ductal adenocarcinoma (PDAC) is highly associated with cachexia and weight loss, which is driven by the tumour's effect on the body. Data are lacking on differences in these metrics based on PDAC anatomic location. We hypothesize that the primary tumour's anatomic region influences the prevalence and severity of unintentional weight loss.
-
The mediation roles of intermuscular fat and inflammation in muscle mitochondrial associations with cognition and mobility J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-20 Qu Tian, Philip R. Lee, Qi Yang, Anne Z. Moore, Bennett A. Landman, Susan M. Resnick, Luigi Ferrucci
Mitochondrial dysfunction may contribute to brain and muscle health through inflammation or fat infiltration in the muscle, both of which are associated with cognitive function and mobility. We aimed to examine the association between skeletal muscle mitochondrial function and cognitive and mobility outcomes and tested the mediation effect of inflammation or fat infiltration.
-
Effect of insulin insufficiency on ultrastructure and function in skeletal muscle J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-20 Chantal Kopecky, Michael Haug, Barbara Reischl, Nandan Deshpande, Bikash Manandhar, Thomas W. King, Victoria Lee, Marc R. Wilkins, Margaret Morris, Patsie Polly, Oliver Friedrich, Kerry-Anne Rye, Blake J. Cochran
Decreased insulin availability and high blood glucose levels, the hallmark features of poorly controlled diabetes, drive disease progression and are associated with decreased skeletal muscle mass. We have shown that mice with β-cell dysfunction and normal insulin sensitivity have decreased skeletal muscle mass. This project asks how insulin deficiency impacts on the structure and function of the remaining
-
Sarcopenia knowledge of geriatric rehabilitation patients is low while they are willing to start sarcopenia treatment: EMPOWER-GR J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-20 Laure M.G. Verstraeten, Amir Mashni, Janneke P. van Wijngaarden, Carel G.M. Meskers, Andrea B. Maier
Sarcopenia is prevalent in 20–50% of geriatric rehabilitation inpatients and is associated with functional dependence and mortality. The aim is to assess knowledge of geriatric rehabilitation inpatients on sarcopenia and their willingness and perceived barriers to start treatment.
-
Inhibition of the skeletal muscle Lands cycle ameliorates weakness induced by physical inactivity J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-20 Justin L. Shahtout, Hiroaki Eshima, Patrick J. Ferrara, J. Alan Maschek, James E. Cox, Micah J. Drummond, Katsuhiko Funai
Lipid hydroperoxides (LOOH) have been implicated in skeletal muscle atrophy with age and disuse. Lysophosphatidylcholine acyltransferase 3 (LPCAT3), an enzyme of the Lands cycle, conjugates a polyunsaturated fatty acyl chain to a lysophospholipid to form a polyunsaturated fatty acid containing phospholipid (PUFA-PL) molecule, providing substrates for LOOH propagation. Previous studies suggest that
-
Validity of the diagnostic criteria from the Asian Working Group for Cachexia in advanced cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-19 Tatsuma Sakaguchi, Keisuke Maeda, Tomoko Takeuchi, Ai Mizuno, Ryoko Kato, Yuria Ishida, Junko Ueshima, Akio Shimizu, Koji Amano, Naoharu Mori
Recently, the Asian Working Group for Cachexia (AWGC) published a consensus statement on diagnostic criteria for cachexia in Asians. We aimed to validate the criteria in adult patients in Japan with advanced cancer.
-
Association of low muscle mass and obesity with increased all-cause and cardiovascular disease mortality in US adults J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-18 Donghyun Kim, Junghoon Lee, Raekil Park, Chang-Myung Oh, Shinje Moon
Sarcopenic obesity, defined as the coexistence of low muscle mass and high adiposity, is associated with cardiovascular disease (CVD) and mortality. However, to what extent sarcopenia contributes to these risks independently or in conjunction with other cardiovascular risk factors remains unclear. This study aimed to investigate the association of low muscle mass, central obesity (COB), metabolic abnormalities
-
Cardiovascular effects of weight loss in old adults with overweight/obesity according to change in skeletal muscle mass J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-18 Xiaojie Cai, Menghui Liu, Xingfeng Xu, Shaozhao Zhang, Rihua Huang, Peng Wang, Lixiang He, Zhuohui Chen, Zishan Liu, Yi Zhou, Yue Guo, Xiaodong Zhuang, Xinxue Liao
Patients with overweight/obesity and type 2 diabetes are encouraged to lose weight, but not all losing weight gain better cardiovascular health, especially old adults. The change in skeletal muscle mass (SMM) could be the key that explains the heterogenous cardiovascular effects of weight loss. This study aims to assess whether the cardiovascular effects of weight loss vary for those gaining skeletal
-
Association between endogenous plasma beta-hydroxy-beta-methylbutyrate levels and frailty in community-dwelling older people J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-13 Begoña Molina-Baena, Jose Antonio Carnicero, Suzette L. Pereira, Francisco José García-García, Angela Santos-Fandila, Ricardo Rueda Cabrera, Leocadio Rodríguez-Mañas
Frailty is a key element in healthy ageing in which muscle performance plays a main role. Beta-hydroxy-beta-methylbutyrate (HMB) supplementation has shown favourable effects in modulating protein synthesis, improving muscle mass and function in interventional studies. Decreased age-related endogenous HMB levels have been shown in previous studies. The aim of the present study is to assess whether there
-
Implication of grip strength assessment for the management of body weight in disability prevention in older adults J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-12 Shu Zhang, Rei Otsuka, Chikako Tange, Yukiko Nishita, Hiroshi Shimokata, Shosuke Satake, Hidenori Arai
Although body mass index (BMI) and grip strength (GS) are both predictors of disability, their joint effect on predicting incident disability remains uncertain. We examined whether the effect of BMI on incident disability can be modulated by GS in community-dwelling older people in Japan.
-
Global epidemiological features and impact of osteosarcopenia: A comprehensive meta-analysis and systematic review J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-12 Shanping Chen, Xiao Xu, Huping Gong, Ruzhao Chen, Lijuan Guan, Xuedan Yan, Lihua Zhou, Yongxue Yang, Jiang Wang, Jianghua Zhou, Chuan Zou, Pan Huang
Osteosarcopenia is defined as the concurrent occurrence of osteopenia/osteoporosis and sarcopenia. The aim of the current study was to perform a systematic review with meta-analysis to determine the global prevalence, risk factors and clinical outcomes of osteosarcopenia. This review was registered in PROSPERO (CRD42022351229). PubMed, Cochrane, Medline and Embase were searched from inception to February
-
Diet quality is associated with adipose tissue and muscle mass: the Coronary Artery Risk Development in Young Adults (CARDIA) study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-12 Masoud Isanejad, Lyn M. Steffen, James G. Terry, James M. Shikany, Xia Zhou, So-YunYi, David R. Jacobs, John Jeffrey Carr, Brian T. Steffen
Aging is associated with changes in body composition, and preventing loss of muscle mass and accumulation of excess adipose tissue in middle-aged adults may reduce age-related conditions at older ages. Dietary intake is one lifestyle factor shown to improve or maintain body composition. However, few studies have examined the Healthy Eating Index2015 (HEI2015), a measure of diet quality, and the association
-
BIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-08 Maria Serova, Blaise Didry-Barca, Robin Deloux, Anne-Sophie Foucault, Stanislas Veillet, René Lafont, Pierre J. Dilda, Mathilde Latil
Muscle aging is associated with a consistent decrease in the ability of muscle tissue to regenerate following intrinsic muscle degradation, injury or overuse. Age-related imbalance of protein synthesis and degradation, mainly regulated by AKT/mTOR pathway, leads to progressive loss of muscle mass. Maintenance of anabolic and regenerative capacities of skeletal muscles may be regarded as a therapeutic
-
Obesity worsens mitochondrial quality control and does not protect against skeletal muscle wasting in murine cancer cachexia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-07 Thomas D. Cardaci, Brandon N. VanderVeen, Brooke M. Bullard, Sierra J. McDonald, Christian A. Unger, Reilly T. Enos, Daping Fan, Kandy T. Velázquez, Norma Frizzell, Espen E. Spangenburg, E. Angela Murphy
More than 650 million people are obese (BMI > 30) worldwide, which increases their risk for several metabolic diseases and cancer. While cachexia and obesity are at opposite ends of the weight spectrum, leading many to suggest a protective effect of obesity against cachexia, mechanistic support for obesity's benefit is lacking. Given that obesity and cachexia are both accompanied by metabolic dysregulation
-
DBC1 maintains skeletal muscle integrity by enhancing myogenesis and preventing myofibre wasting J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-07 Na Liang, Jia He, Jiaqi Yan, Xueying Han, Xiaoqian Zhang, Yamei Niu, Wuga Sha, Jun Li
Skeletal muscle atrophy, particularly ageing-related muscular atrophy such as sarcopenia, is a significant health concern. Despite its prevalence, the underlying mechanisms remain poorly understood, and specific approved medications are currently unavailable. Deleted in breast cancer 1 (DBC1) is a well-known regulator of senescence, metabolism or apoptosis. Recent reports suggest that DBC1 may also
-
Skeletal muscle atrophy in clinical and preclinical models of chronic kidney disease: A systematic review and meta-analysis J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-07 Ashley D. Troutman, Eliott Arroyo, Elizabeth M. Sheridan, Duncan J. D'Amico, Peyton R. Brandt, Rachel Hinrichs, Xiwei Chen, Kenneth Lim, Keith G. Avin
Patients with chronic kidney disease (CKD) are often regarded as experiencing wasting of muscle mass and declining muscle strength and function, collectively termed sarcopenia. The extent of skeletal muscle wasting in clinical and preclinical CKD populations is unclear. We evaluated skeletal muscle atrophy in preclinical and clinical models of CKD, with multiple sub-analyses for muscle mass assessment
-
A simple medical device development according to normative values of calf circumference across ages: results from the Italian Longevity Check-up 7+ (Lookup 7+) project J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-06 Anna Maria Martone, Francesca Ciciarello, Vincenzo Galluzzo, Riccardo Calvani, Maria Beatrice Zazzara, Matteo Tosato, Hélio José Coelho-Junior, Emanuele Marzetti, Francesco Landi
Wide consensus exists on the notion that low muscle mass is a predictor of negative health-related events, such as disability, morbidity, and mortality. Indeed, the European Working Group on Sarcopenia in Older People 2 had identified muscle mass as the key component to confirm the diagnosis of sarcopenia. However, the lack of normative values for muscle mass across ages hampers the practical assessment
-
Cross-sectional and longitudinal association between atrial fibrillation and sarcopenia: Findings from the Korean frailty and aging cohort study J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-06 Ga Yang Shim, Miji Kim, Chang Won Won
Sarcopenia is commonly observed in patients with cardiovascular diseases. However, studies on the association between sarcopenia and atrial fibrillation and their causal relationships are limited. We performed cross-sectional and longitudinal analyses to investigate the association between sarcopenia and atrial fibrillation among community-dwelling older adults.
-
Using magnetic resonance imaging to measure head muscles: An innovative method to opportunistically determine muscle mass and detect sarcopenia J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-04 Miguel German Borda, Gustavo Duque, Mario Ulises Pérez-Zepeda, Jonathan Patricio Baldera, Eric Westman, Anna Zettergren, Jessica Samuelsson, Silke Kern, Lina Rydén, Ingmar Skoog, Dag Aarsland
Sarcopenia is associated with multiple adverse outcomes. Traditional methods to determine low muscle mass for the diagnosis of sarcopenia are mainly based on dual-energy X-ray absorptiometry (DXA), whole-body magnetic resonance imaging (MRI) and bioelectrical impedance analysis. These tests are not always available and are rather time consuming and expensive. However, many brain and head diseases require
-
Comment on “Effects of Vivifrail multicomponent intervention on functional capacity” by Casas-Herrero et al.—The authors reply J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-03 Juan Luis Sánchez-Sánchez, Mikel Izquierdo, Mikel L. Sáez de Asteasu, Iván Antón-Rodrigo, Arkaitz Galbete, Alejandro Álvarez-Bustos, Álvaro Casas-Herrero
In this response letter, we would like to clarify some aspects related to the methodology and inferences derived from our work entitled ‘Effects of Vivifrail multicomponent intervention on functional capacity’,1 which was aimed at investigating the effects of a home-based multicomponent individualized exercise programme (Vivifrail) on the functional capacity of frail older adults with mild cognitive
-
Lack of vitamin D signalling shifts skeletal muscles towards oxidative metabolism J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-12-02 Anamica Das, Neha Jawla, Vaidehee Meena, Suchitra D. Gopinath, Gopalakrishnan Aneeshkumar Arimbasseri
Mice lacking vitamin D receptor (VDR) exhibit a glycogen storage disorder, disrupting carbohydrate utilization in muscle. Here, we asked if the defective carbohydrate metabolism alters the fat utilization by the skeletal muscles of vdr−/− mice.
-
The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-11-28 Tateaki Naito, Hidetaka Wakabayashi, Sakiko Aso, Masaaki Konishi, Masakazu Saitoh, Vickie E. Baracos, Andrew J. Coats, Stefan D. Anker, Lawrence Sherman, Tatiana Klompenhouwer, Noriyasu Shirotani, Akio Inui, Hidenori Arai
Cancer cachexia is a severe complication of advanced malignancy, with few therapeutic options. To promote interprofessional care for cancer cachexia, healthcare providers' needs should be addressed in detail. This pre-planned subgroup analysis of the Global Educational Needs Evaluation: a systemic interprofessional study in cancer cachexia (GENESIS-CC) survey aimed to identify barriers to interprofessional
-
Vitamin K1 ameliorates lipopolysaccharide-triggered skeletal muscle damage revealed by faecal bacteria transplantation J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-11-28 Yuru Xiao, Jianguo Feng, Jing Jia, Jie Li, Yingshun Zhou, Zhangyong Song, Fasheng Guan, Xuexin Li, Li Liu
Sepsis-associated muscle weakness is common in patients of intensive care units (ICUs), and it is closely associated with poor outcomes. The mechanism of sepsis-induced muscle weakness is unclear. Recent studies have found that gut microbiota and metabolites are involved in the regulation of skeletal muscle mass and metabolism. This study aimed to investigate the effects of gut microbiota and metabolites
-
Effectiveness of a randomized intervention by a geriatric team in frail hospital inpatients in non-geriatric settings: FRAILCLINIC project J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-11-28 Marta Checa-López, Alba Costa-Grille, Alejandro Álvarez-Bustos, Jose A. Carnicero-Carreño, Alan Sinclair, Angelo Scuteri, Francesco Landi, Juan José Solano-Jaurrieta, Srikanth Bellary, Leocadio Rodríguez-Mañas
Little research has been undertaken on the benefits of frailty management within different hospital settings. The objective of this study is to provide evidence on the viability and effectiveness of frailty management in non-geriatric hospital settings on mortality and functional decline after discharge.
-
Effects of measurement protocols and repetitions on handgrip strength weakness and asymmetry in patients with cancer J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-11-28 Xiaoyan Chen, Lingling Xie, Xin Xia, Xiaozhen Luo, Jing Chen, Jing Zhang, QinLan Li, Xuemei Zhang, Jiaojiao Jiang, Ming Yang
The use of handgrip strength (HGS) in clinical cancer research is surging. The association between HGS and outcomes in patients with cancer varied across studies, which might be due to the different measurement protocols for HGS. We aimed to answer three questions: (1) Did the use of various protocols for HGS, along with different numbers of repetitions, lead to significant differences in maximum HGS
-
Handelin alleviates cachexia- and aging-induced skeletal muscle atrophy by improving protein homeostasis and inhibiting inflammation J. Cachexia Sarcopenia Muscle (IF 8.9) Pub Date : 2023-11-27 Hui-Jie Zhang, Ben-Hui Wang, Xiang Wang, Chun-Ping Huang, Si-Man Xu, Jia-Li Wang, Tian-E Huang, Wan-Li Xiao, Xiao-Li Tian, Xin-Qiang Lan, Qi-Quan Wang, Yang Xiang
Handelin is a bioactive compound from Chrysanthemum indicum L. that improves motor function and muscle integrity during aging in Caenorhabditis elegans. This study aimed to further evaluate the protective effects and molecular mechanisms of handelin in a mouse muscle atrophy model induced by cachexia and aging.